← Back
Data updated: Jun 28, 2026
60 DEGREES PHARMS
Pharma Pharmaceuticals
60 DEGREES PHARMS is a pharmaceutical company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
60 DEGREES PHARMS's Key Drugs
60 DEGREES PHARMS's core commercial portfolio centers on ARAKODA — its most strategically important drugs approved in the last 15 years.
60 DEGREES PHARMS's Recent FDA Approvals
New NDA/BLA approvals for 60 DEGREES PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
60 DEGREES PHARMS's Therapeutic Areas
Disease areas where 60 DEGREES PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
60 DEGREES PHARMS Pipeline Snapshot
Active clinical trials for 60 DEGREES PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ARAKODA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-08-08
- Latest
- 2022-02-25
- Applications
- 1